> Eli Lilly’s pill works in a similar way to Wegovy, Ozempic, and Novo Nordisk’s diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person’s appetite and regulate blood sugar.

(These three are all just different names for Semaglutide.)

> But unlike those three medications, Eli Lilly’s pill is not a peptide medication.

> ...

> But so-called small molecule pills [orforglipron] will at least be easier for Eli Lilly to manufacture than injections.

The Wikipedia pages are decent -- the picture makes it fairly obvious how much smaller (in terms of # atoms) orforglipron is than tirzepatide even if you don't know how to read chemical structures; just count atoms!

https://en.wikipedia.org/wiki/Orforglipron

https://en.wikipedia.org/wiki/Tirzepatide

No, the molecule (per wikipedia) is significantly smaller.

When the news is this fast and loose with anything that even looks like a fact how am I not to see this as rank manipulation? There is nothing critical in this article except for how hard doctors and insurance companies might be pressed to prescribe it.

Then they end with this gem:

"But Seigerman said it will also put pressure on smaller companies developing pills, such as Structure Therapeutics, to find a partner that can help them compete in the weight loss drug market with pharmaceutical behemoths like Eli Lilly. "

Oh. I see. It's not just manipulation but dumb protectionist gate keeping.

Depressing.

That's pretty substantial. Obviously no one knows what Phase 3 will show, but cynicism seems unwarranted at this point.

https://investor.lilly.com/news-releases/news-release-detail...

If Deflate had not been picked as compression algorithm name, it surely would be a fine name for a weight loss drug.